Quarterly Result29 Jul 2026, 01:14 pm
Eris Lifesciences Declares Q1 FY27 Unaudited Financial Results
AI Summary
Eris Lifesciences Ltd announced that its Board of Directors, in a meeting held on July 29, 2026, approved and took on record the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also submitted the limited review report with unmodified opinions and details as per Regulation 52(4) of SEBI Listing Regulations. Additionally, the Board re-appointed M/s Kiran J. Mehta & Co. as the Cost Auditors for the financial year 2026-27. The board meeting commenced at 11:30 A.M. and concluded at 01:00 P.M.
Key Highlights
- Board approved unaudited financial results for Q1 FY27.
- Results were declared on a standalone and consolidated basis.
- Limited review reports submitted with unmodified opinions.
- Cost Auditors re-appointed for FY 2026-27.
- Disclosure made as per SEBI Listing Regulations.
Price Impact
More from ERIS